COARE BIOTECHNOLOGY, INC.

Biotech · Private

Raphtuzumab, a humanized monoclonal antibody targeting DCLK1 tumor stem cell marker for pancreatic cancer treatment

Grants
$3.5M
4 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Development of an ADC against Pancreatic Cancer$225,000
Federal grantDepartment of Health and Human Services · Phase I · Development of ADC to Target Tumor Stem Cells In Colorectal Cancer$224,950
Federal grantDepartment of Health and Human Services · Phase II · Development of Monoclonal Antibodies to Treat Pancreatic Cancer$2,000,000
Federal grantDepartment of Health and Human Services · Phase II · Development of Monoclonal Antibodies to Treat Pancreatic Cancer$1,094,011
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1306INVENIO THERAPEUTICS INC——
1307CONFOMETRX, INC.——
1308Cavatar LLC——
1309COARE BIOTECHNOLOGY, INC.——
1310Pinnacle Medicines——
1311Riptide Bioscience, Inc.——
1312TING THERAPEUTICS LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.